Figure 4.
Predicted FPG (a) and HbA1c (b) treatment effects (blue lines) vs. placebo disease progression (red lines) after 13 weeks of anakinra treatment (red area) and 39-week follow-up (blue area). Black points with bars in b represent HbA1c data (means ± SEM) for anakinra responders extracted from Larsen et al.5,6 FPG, fasting plasma glucose; SoC, standard of care.